

REMARKS

Claims 1-64 were pending in the present application. By virtue of this response, claims 2, 3, 6, 7, 9, 10, 15, and 16 have been amended. Accordingly, claims 1-64 are currently under consideration. Amendment and cancellation of certain claims is not to be construed as a dedication to the public of any of the subject matter of the claims as previously presented. No new matter has been added.

The specification has been amended to make reference to the SEQ ID numbers of the nucleotide and amino acid sequences disclosed therein. No new matter has been added. If it is determined that a telephone conference would expedite the prosecution of this application, the Examiner is invited to telephone the undersigned at the number given below.

The amendment to the specification on paragraph [0079], line 3, replace the typographical error of TTTGN8 with TTTGN₈.

CONCLUSION

In view of the above, each of the presently pending claims in this application is believed to be in immediate condition for allowance. Accordingly, the Examiner is respectfully requested to withdraw the outstanding rejection of the claims and to pass this application to-issue. If it is determined that a telephone conference would expedite the prosecution of this application, the Examiner is invited to telephone the undersigned at the number given below.

In the event the U.S. Patent and Trademark Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. **03-1952** referencing docket no. 293102003600. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: June 22, 2006

Respectfully submitted,

By 

Terri Shieh-Newton

Registration No.: 47,081

MORRISON & FOERSTER LLP

755 Page Mill Road

Palo Alto, California 94304

(650) 813-5777